PD-1

[Cell Reports Methods] Scientists showed that fibroblastic, hepatic, or neural tumors were all efficiently infiltrated and partially or totally rejected by autologous immune cells in humanized mice.

[Nature Communications] Scientists found that intermittent but not daily dosing of a PI3Kα/β/δ inhibitor, BAY1082439, on Pten-null prostate cancer models could overcome immune checkpoint therapy resistance and unleash CD8+ T cell-dependent anti-tumor immunity in vivo.

[Oncogene] Scientists reported that both PD-L1 and JMJD2D were frequently overexpressed in human colorectal cancer specimens with a significant positive correlation.

[Journal of Immunology Research] Scientists generated a therapeutic chimeric protein containing the PD-L1 single-chain variable fragment linked to a cleavable model cytotoxic T lymphocyte epitope: E7 CTL peptide.

[Journal of Immunology] Using a mouse model of sepsis, scientists found that the long noncoding RNA HOXA transcript antisense RNA myeloid-specific 1 (HOTAIRM1) was highly expressed in mice during the late phase of sepsis.

[BioAtla, Inc. (PR Newswire, Inc.)] BioAtla, Inc. announced that it has entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla's two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb's anti-PD-1 therapy nivolumab.